Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official Title: Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo: A Phase 2A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial
Brief Summary:
This is a phase 2A clinical trial designed to test the pro-melanogenic and anti-inflammatory role of phosphodiesterase-4 inhibitors (PDE4i), alone and in combination with active narrow band UVB (NBUVB), in vitiligo lesions. This is a double-blind, randomized controlled trial (RCT) with six study arms. The goal is for 64 participants to be recruited and complete the study.
Actual Study Start Date: September 7, 2022
Estimated Study Completion Date: July 2023
https://beta.clinicaltrials.gov/study/NCT05298033
FAQOther Questions
- Is there a traditional medicine to treat vitiligo?
Traditional medicines may be helpful in chronic, metabolic, and stress-related conditions early in the disease manifestation, before extensive tissue and organ damage has occurr...
- Any Link Between Vitiligo and Military Service?
While there isn't specific research directly linking military service to the onset of vitiligo, it's critical to comprehend that vitiligo is a multifaceted disorder influenced b...
- Does halo nevi affect vitiligo development?
Halo nevi (also known as Sutton's nevi) are characterized by a mole that's surrounded by a ring of depigmented or lighter skin. While both halo nevi and vitiligo involve the des...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.